Efficacy of tocilizumab in patients with severe COVID-19 : Survival and clinical outcomes
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: SARS-CoV-2 is associated with a severe inflammatory response contributing to respiratory and systemic manifestations, morbidity, and mortality in patients with coronavirus disease 2019 (COVID-19).
METHODS: Tocilizumab (TCZ) efficacy on mortality and length of hospital stay was retrospectively evaluated in patients who received TCZ and compared with that in controls with a similar severity of COVID-19. The primary endpoint was survival probability on day 28. The secondary endpoints included survival at day 14 and length of hospital stay.
RESULTS: Of the 148 patients included in the study, 62 received TCZ and standard of care, whereas 86 served as a control group and received only standard of care. The two groups were similar, although TCZ-treated patients were more likely to exhibit hypertension (46.7% vs. 29.8%), chronic kidney disease (14.5% vs. 1.1%), and high Charlson score (1.18 vs. 1.00; p = 0.006) and less likely to receive corticosteroid treatment (48.5% vs. 93.0%). TCZ was associated with lower mortality on both day 28 (16.1% vs. 37.2%, p = 0.004) and day 14 (9.7% vs. 24.4%, p = 0.022). The hospital stay was longer in the TCZ-treated than in the control group (15.6 ± 7.59 vs.17.7 ± 7.8 days, p = 0.103). Ten patients (16.0%) in the TCZ-treated group developed infections.
CONCLUSION: TCZ was associated with a lower likelihood of death despite resulting in higher infection rates and a non-significant longer hospital stay.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Journal of infection and public health - 14(2021), 8 vom: 21. Aug., Seite 1021-1027 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al-Baadani, Abeer [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 03.08.2021 Date Revised 02.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jiph.2021.05.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327011416 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327011416 | ||
| 003 | DE-627 | ||
| 005 | 20240402233837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jiph.2021.05.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1360.xml |
| 035 | |a (DE-627)NLM327011416 | ||
| 035 | |a (NLM)34153727 | ||
| 035 | |a (PII)S1876-0341(21)00150-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al-Baadani, Abeer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of tocilizumab in patients with severe COVID-19 |b Survival and clinical outcomes |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.08.2021 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: SARS-CoV-2 is associated with a severe inflammatory response contributing to respiratory and systemic manifestations, morbidity, and mortality in patients with coronavirus disease 2019 (COVID-19) | ||
| 520 | |a METHODS: Tocilizumab (TCZ) efficacy on mortality and length of hospital stay was retrospectively evaluated in patients who received TCZ and compared with that in controls with a similar severity of COVID-19. The primary endpoint was survival probability on day 28. The secondary endpoints included survival at day 14 and length of hospital stay | ||
| 520 | |a RESULTS: Of the 148 patients included in the study, 62 received TCZ and standard of care, whereas 86 served as a control group and received only standard of care. The two groups were similar, although TCZ-treated patients were more likely to exhibit hypertension (46.7% vs. 29.8%), chronic kidney disease (14.5% vs. 1.1%), and high Charlson score (1.18 vs. 1.00; p = 0.006) and less likely to receive corticosteroid treatment (48.5% vs. 93.0%). TCZ was associated with lower mortality on both day 28 (16.1% vs. 37.2%, p = 0.004) and day 14 (9.7% vs. 24.4%, p = 0.022). The hospital stay was longer in the TCZ-treated than in the control group (15.6 ± 7.59 vs.17.7 ± 7.8 days, p = 0.103). Ten patients (16.0%) in the TCZ-treated group developed infections | ||
| 520 | |a CONCLUSION: TCZ was associated with a lower likelihood of death despite resulting in higher infection rates and a non-significant longer hospital stay | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hospital stay | |
| 650 | 4 | |a Interleukin-6 | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 4 | |a Survival | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Eltayeb, Nazik |e verfasserin |4 aut | |
| 700 | 1 | |a Alsufyani, Eid |e verfasserin |4 aut | |
| 700 | 1 | |a Albahrani, Salma |e verfasserin |4 aut | |
| 700 | 1 | |a Basheri, Shareefah |e verfasserin |4 aut | |
| 700 | 1 | |a Albayat, Hawra |e verfasserin |4 aut | |
| 700 | 1 | |a Batubara, Enas |e verfasserin |4 aut | |
| 700 | 1 | |a Ballool, Sulafa |e verfasserin |4 aut | |
| 700 | 1 | |a Al Assiri, Ayed |e verfasserin |4 aut | |
| 700 | 1 | |a Faqihi, Fahad |e verfasserin |4 aut | |
| 700 | 1 | |a Musa, Ali B |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, Asirvatham A |e verfasserin |4 aut | |
| 700 | 1 | |a Alsherbeeni, Nisreen |e verfasserin |4 aut | |
| 700 | 1 | |a Elzein, Fatehi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection and public health |d 2008 |g 14(2021), 8 vom: 21. Aug., Seite 1021-1027 |w (DE-627)NLM200240730 |x 1876-035X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:8 |g day:21 |g month:08 |g pages:1021-1027 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jiph.2021.05.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 8 |b 21 |c 08 |h 1021-1027 | ||